Silence Therapeutics plc (FRA:XRP2)

Market Cap	191.63M -21.5%
Revenue (ttm)	22.01M +40.4%
Net Income	-55.01M
EPS	-1.16
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	3.920
Previous Close	4.080
Day's Range	3.920 - 3.920
52-Week Range	1.700 - 6.550
Beta	n/a
RSI	36.70
Earnings Date	Feb 26, 2026

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, includin...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1994
• Employees: 116
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: XRP2

Financial Performance

In 2024, Silence Therapeutics's revenue was $43.26 million, an increase of 36.71% compared to the previous year's $31.64 million. Losses were -$45.31 million, -16.45% less than in 2023.

Financial numbers in USD